myelodysplastic syndrome (MDS)

By Targets:	Apoptosis (3) Aurora Kinase (2) Casein Kinase (1) DNA Methyltransferase (2) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Glutathione S-transferase (2) Interleukin Related (1) IRAK (1) Isocitrate Dehydrogenase (IDH) (1) Ligands for E3 Ligase (1) Molecular Glues (1) MyD88 (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (1) P-glycoprotein (1) PDGFR (2) Tau Protein (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) VEGFR (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Nucleosides and their Analogs (1) U (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15229

Guadecitabine sodium Maximum Cited Publications 10 Publications Verification SGI-110 sodium; S-110 sodium	DNA Methyltransferase	Cancer
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

HY-139076

Menin-MLL inhibitor 19	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-132189

Laniquidar	P-glycoprotein	Cancer
Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC₅₀ of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters . Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . Laniquidar has limited oral bioavailability .

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-159646

BMS-986397	Molecular Glues Ligands for E3 Ligase Casein Kinase Apoptosis	Cancer
BMS-986397 is a cereblon-based CK1α (casein kinase 1α) molecular glue degrader that can cause rapid apoptosis and cell cycle arrest in TP53 wild-type AML (acute myeloid leukemia) cells. BMS-986397 can be used for the study of AML and HR-MDS (High-Risk Myelodysplastic Syndrome) .

HY-113061

Pseudouridine	Endogenous Metabolite Nucleoside Antimetabolite/Analog DNA/RNA Synthesis	Cancer
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .

HY-176197

IRAK4-IN-31	IRAK	Cancer
IRAK4-IN-31 (Compound II) is a crystalline IRAK4 inhibitor. IRAK4-IN-31 can be used in myelodysplastic syndrome (MDS) research .

HY-13542

Guadecitabine SGI-110	DNA Methyltransferase	Cancer
Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

HY-13634

Ezatiostat hydrochloride TER199; TLK199 hydrochloride	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-13634A

Ezatiostat 5+ Cited Publications TER199(free base); TLK199	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .

HY-114226

Olutasidenib 1 Publications Verification FT-2102	Isocitrate Dehydrogenase (IDH)	Inflammation/Immunology Cancer
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC₅₀ values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

Cat. No.	Product Name	Target	Research Area

HY-13634A

Ezatiostat 5+ Cited Publications TER199(free base); TLK199	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .

HY-13634

Ezatiostat hydrochloride TER199; TLK199 hydrochloride	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .

Cat. No.	Product Name	Target	Research Area

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-P99555

Tomaralimab OPN-305	Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113061

Pseudouridine	Structural Classification Natural Products Human Gut Microbiota Metabolites Other disease Classification of Application Fields Source classification Disease markers Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite Nucleoside Antimetabolite/Analog DNA/RNA Synthesis
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .

Cat. No.	Product Name		Classification

HY-113061

Pseudouridine		Nucleosides and their Analogs U
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia. .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.

myelodysplastic syndrome (MDS)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products